188259-69-0 Usage
Uses
Used in Pharmaceutical Industry:
4-Hydroxy Valsartan, Mixture of Diastereomers is used as a nonpeptide angiotensin II AT1-receptor antagonist for treating hypertension and heart failure. It helps in blocking the effects of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and the workload on the heart.
Used in Cardiovascular Applications:
4-Hydroxy Valsartan, Mixture of Diastereomers is used as a therapeutic agent for cardiovascular conditions due to its ability to reduce blood pressure and improve heart function. It is particularly beneficial in managing conditions like hypertension, heart failure, and post-myocardial infarction.
Used in Research and Development:
4-Hydroxy Valsartan, Mixture of Diastereomers is used as a research compound for studying the mechanisms of angiotensin II type 1 receptor antagonism and its potential applications in various cardiovascular and renal diseases. It aids in the development of new drugs and therapies targeting the renin-angiotensin system.
Check Digit Verification of cas no
The CAS Registry Mumber 188259-69-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,8,2,5 and 9 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 188259-69:
(8*1)+(7*8)+(6*8)+(5*2)+(4*5)+(3*9)+(2*6)+(1*9)=190
190 % 10 = 0
So 188259-69-0 is a valid CAS Registry Number.
InChI:InChI=1/C24H29N5O4/c1-15(2)22(24(32)33)29(21(31)13-8-16(3)30)14-17-9-11-18(12-10-17)19-6-4-5-7-20(19)23-25-27-28-26-23/h4-7,9-12,15-16,22,30H,8,13-14H2,1-3H3,(H,32,33)(H,25,26,27,28)/t16?,22-/m0/s1
188259-69-0Relevant academic research and scientific papers
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
Waldmeier,Flesch,Mueller,Winkler,Kriemler,Buehlmayer,De Gasparo
, p. 59 - 71 (2007/10/03)
1. The disposition of valsartan, a potent angiotensin II receptor antagonist, was investigated in six healthy male volunteers. They each received a single oral dose of 80 mg of a 14C-labelled preparation as a neutral buffered solution. 2. Peak
